EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Impact of lung cancer screening on stage migration and mortality among the national Veterans Health Administration population with lung cancer

Donna M Edwards iD, Mina Pirzadeh iD, Tony Van, Ralph Jiang, Akshay Tate, Grace Schaefer, Jadyn James, Caroline Bishop, Cydnee Wilson, Nicholas Nedzesky, Aaren Alseri, Anthony Leveque und 9 weitere

Cancer · 2024-09 · 130 (17) · 2910-2917

DOI: 10.1002/cncr.35340 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, online erschienen am 10.06.2024. Verfasst von Donna M Edwards und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Lung Neoplasms, Early Detection of Cancer, United States Department of Veterans Affairs, Neoplasm Staging. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: BLRD VA, NCI NIH HHS, Lung Precision Oncology Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite randomized trials demonstrating a mortality benefit to low‐dose computed tomography screening to detect lung cancer, uptake of lung cancer screening (LCS) has been slow, and the benefits of screening remain unclear in clinical practice.

Methods

This study aimed to assess the impact of screening among patients in the Veterans Health Administration (VA) health care system diagnosed with lung cancer between 2011 and 2018. Lung cancer stage at diagnosis, lung cancer–specific survival, and overall survival between patients with cancer who did and did not receive screening before diagnosis were evaluated. We used Cox regression modeling and inverse propensity weighting analyses with lead time bias adjustment to correlate LCS exposure with patient outcomes.

Results

Of 57,919 individuals diagnosed with lung cancer in the VA system between 2011 and 2018, 2167 (3.9%) underwent screening before diagnosis. Patients with screening had higher rates of stage I diagnoses (52% vs. 27%; p ≤ .0001) compared to those who had no screening. Screened patients had improved 5‐year overall survival rates (50.2% vs. 27.9%) and 5‐year lung cancer–specific survival (59.0% vs. 29.7%) compared to unscreened patients. Among screening‐eligible patients who underwent National Comprehensive Cancer Network guideline–concordant treatment, screening resulted in substantial reductions in all‐cause mortality (adjusted hazard ratio [aHR], 0.79; 95% confidence interval [CI], 0.67–0.92; p = .003) and lung‐specific mortality (aHR, 0.61; 95% CI, 0.50–0.74; p < .001).

Conclusions

While LCS uptake remains limited, screening was associated with earlier stage diagnoses and improved survival. This large national study corroborates the value of LCS in clinical practice; efforts to widely adopt this vital intervention are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsEarly Detection of CancerUnited States Department of Veterans AffairsNeoplasm StagingHumansMaleFemaleAgedMiddle AgedUnited StatesTomography, X-Ray ComputedSurvival RateVeterans HealthMass ScreeningVeterans

Stichwörter der Autor:innen

cancer outcomesearly detection of cancerlung cancer screeninglung neoplasms

Autor:innen und Institutionen

  • Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA.
  • Department of Radiation Oncology, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan, USA.
  • Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Division of Pulmonary and Critical Care, Department of Medicine, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan, USA.
  • Center for Clinical Management Research, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan, USA.
  • Department of Biostatistics, University of Michigan, Ann Arbor, Michigan, USA.

ORCID-Profile: Donna M Edwards, Mina Pirzadeh, Alex K Bryant, Michael D Green

Förderung

  • BLRD VA
  • NCI NIH HHS
  • Lung Precision Oncology Program
  • LUNGevity Foundation
  • Melanoma Research Alliance

Zitieren

APA

Edwards, D. M., Pirzadeh, M., Van, T., Jiang, R., Tate, A., Schaefer, G., James, J., Bishop, C., Wilson, C., Nedzesky, N., Alseri, A., Leveque, A., Malus, A., Waljee, A., Elliott, D. A., Deng, J., Schwartz, A., Schipper, M., Bryant, A. K., …, & Green, M. D. (2024). Impact of lung cancer screening on stage migration and mortality among the national Veterans Health Administration population with lung cancer. Cancer, 130(17), 2910-2917. https://doi.org/10.1002/cncr.35340

Vancouver

Edwards DM, Pirzadeh M, Van T, Jiang R, Tate A, Schaefer G, et al. Impact of lung cancer screening on stage migration and mortality among the national Veterans Health Administration population with lung cancer. Cancer. 2024;130(17):2910-2917. doi:10.1002/cncr.35340

BibTeX
@article{Edwards2024,
  author = {Edwards, Donna M and Pirzadeh, Mina and Van, Tony and Jiang, Ralph and Tate, Akshay and Schaefer, Grace and James, Jadyn and Bishop, Caroline and Wilson, Cydnee and Nedzesky, Nicholas and Alseri, Aaren and Leveque, Anthony and Malus, Amanda and Waljee, Akbar and Elliott, David A and Deng, Jane and Schwartz, Ann and Schipper, Matthew and Bryant, Alex K and Ramnath, Nithya and Green, Michael D},
  title = {Impact of lung cancer screening on stage migration and mortality among the national Veterans Health Administration population with lung cancer},
  journal = {Cancer},
  year = {2024},
  volume = {130},
  number = {17},
  pages = {2910--2917},
  doi = {10.1002/cncr.35340}
}
Kostenlos starten →